Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (ADPACA)

Medical University of Graz

Status

Enrolling

Conditions

Advanced Pancreatic Carcinoma

Pancreatic Cancer

Treatments

Drug: all approved chemotherapeutic agents from second line

Study type

Observational

Funder types

Other

Identifiers

NCT05526443

ADPACA

Details and patient eligibility

About

To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria

Full description

1500 adult patients with locally advanced inoperable and/or metastasized PDAC undergoing first line chemotherapy

Enrollment

1,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years, female and male
ECOG (Eastern Cooperative Oncology Group) Scale 0-2
Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
Signed informed consent for prospective patients, for retrospective cases no informed consent is required

Exclusion criteria

Patients with locally advanced operable PDAC who do not receive palliative chemotherapy
Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy